FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis.
Autor: | Jiménez Morales A; Pharmacy Service, UGC Provincial de Farmacia de Granada, University Hospital Virgen de las Nieves, Granada, Spain., Maldonado-Montoro M; Pharmacy Service, UGC Provincial de Farmacia de Granada, University Hospital Virgen de las Nieves, Granada, Spain., Martínez de la Plata JE; Pharmacy Service, Hospital de Poniente-El Ejido, El Ejido (Almería), Spain., Pérez Ramírez C; Pharmacy Service, UGC Provincial de Farmacia de Granada, University Hospital Virgen de las Nieves, Granada, Spain.; Department of Biochemistry, Faculty of Pharmacy, University of Granada, Granada, Spain., Daddaoua A; Department of Biochemistry, Faculty of Pharmacy, University of Granada, Granada, Spain., Alarcón Payer C; Pharmacy Service, UGC Provincial de Farmacia de Granada, University Hospital Virgen de las Nieves, Granada, Spain., Expósito Ruiz M; Fundación Pública Andaluza para la Investigación Biosanitaria de Andalucía Oriental 'Alejandro Otero' (FIBAO), University Hospital Virgen de las Nieves, Granada, Spain., García Collado C; Pharmacy Service, UGC Provincial de Farmacia de Granada, University Hospital Virgen de las Nieves, Granada, Spain. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of clinical pharmacology [J Clin Pharmacol] 2019 Apr; Vol. 59 (4), pp. 517-531. Date of Electronic Publication: 2018 Nov 20. |
DOI: | 10.1002/jcph.1341 |
Abstrakt: | We evaluated the influence of clinical, biochemical, and genetic factors on response in 142 patients diagnosed with rheumatoid arthritis, of whom 87 patients were treated with tocilizumab (61.26%) and 55 patients were treated with rituximab (38.7%;) according to the variables European League Against Rheumatism (EULAR) response, remission, low disease activity, and improvement in Disease Activity Score, 28 joints (DAS28) at 6, 12, and 18 months. A retrospective prospective cohort study was conducted. Patients carrying the FCGR3A rs396991-TT genotype treated with tocilizumab showed higher EULAR response (OR, 5.075; 95%CI, 1.20-21.33; P = .027) at 12 months, those who were naive for biological disease-modifying antirheumatic drugs (bDMARDs) at the beginning of treatment showed satisfactory EULAR response, higher remission, and greater improvement in DAS28 at 6 months. Younger age at start of tocilizumab treatment was associated with satisfactory EULAR response at 18 months and greater remission at 6 and 18 months. Subcutaneous tocilizumab administration was associated with higher remission at 6 months and improved low disease activity rate at 12 months. In patients treated with rituximab, carriers of the FCGR2A rs1801274-TT genotype had higher EULAR response at 6 months (OR, 4.861; 95%CI, 1.11-21.12; P = .035), 12 months (OR, 4.667; p = 0.066, 95%CI, 0.90-24.12; P = .066), and 18 months (OR, 2.487; 95%CI, 0.35-17.31; P = .357), higher remission (OR: 10.625; p = 0.044, CI (© 2018, The American College of Clinical Pharmacology.) |
Databáze: | MEDLINE |
Externí odkaz: |